Investigating new treatments for age-related macular degeneration
Official title: Retinoid cycles and retinal disease treatment
Funded at Veterans Health Administration · NIH-11061800 · Data updated 2026-11-12
This study is looking at how certain vitamin A-related compounds might help improve vision for older adults with age-related macular degeneration (AMD), and it aims to find new treatments that could make life better for those dealing with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Health Administration NIH-funded |
| Lab location | 1 site (Long Beach, United States) |
| Project start | April 1, 2020 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| NIH project number | 5I01BX004939-06 |
| Project ID | NIH-11061800 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 65 and older who are experiencing symptoms of age-related macular degeneration.
✕Less likely to help
Patients under the age of 65 or those without age-related macular degeneration may not benefit from this research.
What this research studies
This research focuses on age-related macular degeneration (AMD), a leading cause of vision loss in older adults. The team aims to explore the role of retinoids, which are compounds related to vitamin A, in treating this condition. By studying how these compounds function at a cellular level, the researchers hope to develop new therapies that could improve vision and quality of life for those affected by AMD. The research involves both laboratory studies and the use of advanced mouse models to better understand the disease mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments that restore or preserve vision for individuals suffering from age-related macular degeneration.
How similar studies have gone: Previous research has shown promise in using retinoid modulation for treating retinal diseases, indicating a potential for success in this approach.
Where this research is happening
-
Veterans Health Administration
Long Beach, United States Active
Researchers
- Principal investigator: Kiser, Philip David — Veterans Health Administration
- Study coordinator: Kiser, Philip David
Related research
Other NIH-funded projects on the same topics.
-
Integrative Curation of Clinically Relevant Variants in X-Linked Inherited Retinal Disease Genes
A project to expand expert review of genetic variants linked to X‑linked inherited retinal diseases so patients can access gene therapies.
-
Intravitreal gene therapy for inherited retinal disease
A specialized gene therapy approach delivered inside the eye is being studied to help children with inherited retinal diseases maintain or improve vision.
-
Retinal Disease: Molecular Basis and Pathophysiology
A gene mutation linked to retinal disease is studied to understand how it changes cellular pathways and leads to vision problems.
-
Genes that change how inherited retinal disorders behave
This work looks for other genes that change how CRB1-related inherited retinal diseases affect children and adults who carry CRB1 mutations.
-
A new antibody drug to restore the retina’s protective barrier
This project tests a novel antibody designed to boost a natural signaling pathway to strengthen the retina’s protective barrier for people with retinal diseases that cause leaking or inflammation.
-
Eye-injection gene therapy for inherited retinal disease
A gene therapy delivered by an injection into the eye aims to treat inherited forms of retinal degeneration, including in children.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.